ArticleJournal of gynecologic oncology2026
Adjuvant sandwich therapy is associated with improved survival in stage III-IVA endometrial cancer: a network meta-analysis.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivePatients with advanced endometrial cancer (International Federation of Gynecology and Obstetrics stages III-IVA) face a high risk of recurrence even after surgery. Although adjuvant chemoradiotherapy (CRT) is standard care, the optimal sequencing strategy remains controversial. This research aimed to evaluate the impact of 4 CRT sequencing strategies on survival in patients with stages III-IVA endometrial cancer.
methodsWe conducted a network meta-analysis of 9 studies, encompassing 8,401 patients, to compare 4 CRT regimens: concurrent CRT (CCRT), chemotherapy followed by radiotherapy (CR), radiotherapy followed by chemotherapy (RC), and sandwich therapy involving chemotherapy-radiotherapy-chemotherapy (CRC). The primary outcomes were overall survival (OS) and progression-free survival (PFS), which were analyzed using risk ratios (RRs) with 95% confidence intervals (CIs). Treatment rankings were determined based on surface under the cumulative ranking (SUCRA) probabilities.
resultsCRC demonstrated superior survival outcomes compared to other regimens, with significantly higher mortality risks observed in comparator groups: for OS, CCRT showed a 99% increased risk (RR=1.99; 95% CI=1.28-3.09), CR 48% (RR=1.48; 95% CI=1.11-1.97), and RC 57% (RR=1.57; 95% CI=1.09-2.26); for PFS, CR exhibited 40% higher recurrence risk (RR=1.40; 95% CI=1.16-1.68) and RC 35% (RR=1.35; 95% CI=1.03-1.77). SUCRA values ranked CRC highest for both OS (92.98%) and PFS (96.32%), with no significant differences in grade ≥3 toxicity across regimens.
conclusionFor patients with stages III-IVA endometrial cancer, CRC is associated with survival benefits without an increase in toxicity. Pending prospective validation, these findings support CRC as the preferred adjuvant regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.